GIFT Does Damage To Idea Of Double Dosing Of Plavix For Poor Responders

Increasing the dose of Plavix (clopidogrel) does not seem to be a sufficient strategy for treating patients who are poor metabolizers of the soon-to-be generic drug, according to a new trial of genetic testing for responders and contrary to a small study currently in labeling of the Bristol-Myers Squibb/Sanofi-Aventis drug.